Trial Profile
CUSTOM-I
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2008
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms CUSTOM-I
- Sponsors Xtent
- 13 Oct 2008 Three-year results presented at the Transcatheter Cardiovascular Therapeutics meeting.
- 24 Oct 2007 New trial record.